These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 17847085)
1. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085 [TBL] [Abstract][Full Text] [Related]
2. A novel ErbB2 epitope targeted by human antitumor immunoagents. Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302 [TBL] [Abstract][Full Text] [Related]
3. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity. Chang L; Zhou C; Xu M; Liu J J Comput Aided Mol Des; 2010 Jan; 24(1):37-47. PubMed ID: 20012671 [TBL] [Abstract][Full Text] [Related]
4. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Nielsen UB; Adams GP; Weiner LM; Marks JD Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810 [TBL] [Abstract][Full Text] [Related]
5. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Neve RM; Nielsen UB; Kirpotin DB; Poul MA; Marks JD; Benz CC Biochem Biophys Res Commun; 2001 Jan; 280(1):274-9. PubMed ID: 11162510 [TBL] [Abstract][Full Text] [Related]
6. Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris. Hu S; Li L; Qiao J; Guo Y; Cheng L; Liu J Protein Expr Purif; 2006 May; 47(1):249-57. PubMed ID: 16403645 [TBL] [Abstract][Full Text] [Related]
7. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. Biburger M; Weth R; Wels WS J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482 [TBL] [Abstract][Full Text] [Related]
8. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Li X; Stuckert P; Bosch I; Marks JD; Marasco WA Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533 [TBL] [Abstract][Full Text] [Related]
9. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389 [TBL] [Abstract][Full Text] [Related]
10. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure. Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496 [TBL] [Abstract][Full Text] [Related]
11. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348 [TBL] [Abstract][Full Text] [Related]
12. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Covaceuszach S; Cattaneo A; Lamba D Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712 [TBL] [Abstract][Full Text] [Related]
13. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. Pavoni E; Flego M; Dupuis ML; Barca S; Petronzelli F; Anastasi AM; D'Alessio V; Pelliccia A; Vaccaro P; Monteriù G; Ascione A; De Santis R; Felici F; Cianfriglia M; Minenkova O BMC Cancer; 2006 Feb; 6():41. PubMed ID: 16504122 [TBL] [Abstract][Full Text] [Related]
14. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Vajdos FF; Adams CW; Breece TN; Presta LG; de Vos AM; Sidhu SS J Mol Biol; 2002 Jul; 320(2):415-28. PubMed ID: 12079396 [TBL] [Abstract][Full Text] [Related]
16. Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design. Qiao C; Lv M; Li X; Geng J; Li Y; Zhang J; Lin Z; Feng J; Shen B J Biomol Struct Dyn; 2013; 31(5):511-21. PubMed ID: 23003339 [TBL] [Abstract][Full Text] [Related]
17. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938 [TBL] [Abstract][Full Text] [Related]
18. Selection of tumor-specific internalizing human antibodies from phage libraries. Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812 [TBL] [Abstract][Full Text] [Related]
19. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181 [TBL] [Abstract][Full Text] [Related]
20. Molecular basis for the binding polyspecificity of an anti-cholera toxin peptide 3 monoclonal antibody. Otte L; Knaute T; Schneider-Mergener J; Kramer A J Mol Recognit; 2006; 19(1):49-59. PubMed ID: 16273596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]